Hiromasa Yamamoto

23PUBLICATIONS
37CO-AUTHORS
Predictive and prognostic markersRadiation therapyTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Allergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Apr 27, 2024
Adrenergic microenvironment driven by cancer-associated Schwann cells contributes to chemoresistance in patients with lung cancer.

Yusuke Otani, Haruyoshi Katayama, Yidan Zhu

|Mar 07, 2024
Impact of the neutrophil-to-lymphocyte ratio on patients with locally advanced non-small cell lung cancer who suffer radiation pneumonitis during the course of induction chemoradiotherapy followed by surgery.

Yujiro Kubo, Hiromasa Yamamoto, Kei Matsubara

|Sep 01, 2023
Prognostic Impact of Tumor-Infiltrating Lymphocytes, Tertiary Lymphoid Structures, and Neutrophil-to-Lymphocyte Ratio in Pulmonary Metastases from Uterine Leiomyosarcoma.

Naoki Matsuda, Hiromasa Yamamoto, Tomohiro Habu

|May 19, 2023
Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201.

Hiromasa Yamamoto, Junichi Soh, Norihito Okumura

|Nov 10, 2022
Functional Blockage of S100A8/A9 Ameliorates Ischemia-Reperfusion Injury in the Lung.

Kentaro Nakata, Mikio Okazaki, Tomohisa Sakaue

|Jul 24, 2022
Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer-associated fibroblast.

Kosuke Ochi, Ken Suzawa, Yin Min Thu

Pageof 4

Frequent Collaborators

11 joint publications

Kazuhiko Shien

9 joint publications

Shinichi Toyooka

4 joint publications

Masakiyo Sakaguchi

2 joint publications

Hidejiro Torigoe